Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Notes Payables (2020 - 2024)

Aytu Biopharma (AYTU) has disclosed Notes Payables for 7 consecutive years, with $4.0 million as the latest value for Q4 2024.

  • Quarterly Notes Payables rose 291.03% to $4.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2024, up 291.03% year-over-year, with the annual reading at $2.4 million for FY2024, 53.23% up from the prior year.
  • Notes Payables for Q4 2024 was $4.0 million at Aytu Biopharma, down from $4.3 million in the prior quarter.
  • The five-year high for Notes Payables was $10.4 million in Q1 2023, with the low at $41318.0 in Q4 2020.
  • Average Notes Payables over 4 years is $3.3 million, with a median of $2.4 million recorded in 2024.
  • The sharpest move saw Notes Payables plummeted 86.19% in 2023, then skyrocketed 291.03% in 2024.
  • Over 4 years, Notes Payables stood at $41318.0 in 2020, then surged by 17880.06% to $7.4 million in 2022, then crashed by 86.19% to $1.0 million in 2023, then surged by 291.03% to $4.0 million in 2024.
  • According to Business Quant data, Notes Payables over the past three periods came in at $4.0 million, $4.3 million, and $2.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.